Qi X-M, Wang J, Xu X-X, Li Y-Y, Wu Y-G
Department of Nephrology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Inflamm Res. 2016 Feb;65(2):103-14. doi: 10.1007/s00011-015-0893-y. Epub 2015 Nov 13.
Several works in the setting of early experimental diabetic nephropathy using anti-inflammatory drugs, such as the calcineurin inhibitor FK506, have shown prevention of the development or amelioration of renal injury including proteinuria. The exact mechanisms by which anti-inflammatory drugs lower the albuminuria have not been still clarified well.
The diabetic rats were induced by using streptozotocin.
The diabetic rats were subjected to oral FK506 treatment at a dose of 0.5 or 1.0 mg/kg daily for 4 weeks.
Renal histology for the ultrastructural evaluation was determined by electron microscope, followed by analyses of renal nephrin and podocin and detection of renal iNOS(+) macrophages and NF-κB-p-p65(+).
Elevated 24-h urinary albumin excretion rate was markedly attenuated by FK506 treatment. In diabetic model rats, FK506 treatment at a dose of 0.5 or 1.0 mg/kg significantly increased the expression of nephrin and podocin when compared to control. As expected, rats in control diabetic group had an increase in GBM thickening and foot process effacement when compared to normal rats; increased GBM thickening and foot process effacement were ameliorated by FK506 treatment with 0.5 and 1.0 mg/kg. Histologically, there was marked accumulation of ED-1(+)cells (macrophages) in diabetic kidneys, and FK506 treatment failed to inhibit it. In contrast, FK506 treatment at 0.5 and 1.0 mg/kg doses significantly inhibited the elevated ED-1(+)/iNOS(+) cells in the kidneys of diabetic rats. ED-1(+)/NF-κB-p-p65(+) cells were significantly increased in positive diabetic kidneys compared to those of normal rats. FK506 treatment at 0.5 and 1.0 mg/kg significantly attenuated the elevated ED-1(+)/NF-κB-p-p65(+) cells in diabetic kidneys. Additionally, a positive correlation was observed between ED-1(+)/iNOS(+) cells and albuminuria (r = 0.87, p < 0.05). Likewise, ED-1(+)/iNOS(+) cells were correlated negatively with both nephrin and podocin protein (r = -0.70, p < 0.05; r = -0.68, p < 0.05, respectively).
Our results show that FK506 not only upregulates expression of nephrin and podocin but also inhibits macrophage activation to protect against podocyte injury.
在早期实验性糖尿病肾病背景下,使用抗炎药物(如钙调神经磷酸酶抑制剂FK506)的多项研究表明,其可预防肾损伤(包括蛋白尿)的发展或改善肾损伤情况。抗炎药物降低蛋白尿的确切机制尚未完全阐明。
使用链脲佐菌素诱导糖尿病大鼠。
糖尿病大鼠每日口服剂量为0.5或1.0毫克/千克的FK506,持续4周。
通过电子显微镜进行肾脏组织学超微结构评估,随后分析肾nephrin和podocin,并检测肾脏iNOS(+)巨噬细胞和NF-κB-p-p65(+)。
FK506治疗显著降低了升高的24小时尿白蛋白排泄率。在糖尿病模型大鼠中,与对照组相比,剂量为0.5或1.0毫克/千克的FK506治疗显著增加了nephrin和podocin的表达。正如预期的那样,与正常大鼠相比,糖尿病对照组大鼠的肾小球基底膜(GBM)增厚和足突消失增加;0.5和1.0毫克/千克的FK506治疗改善了GBM增厚和足突消失情况。组织学上,糖尿病肾脏中ED-1(+)细胞(巨噬细胞)有明显积聚,FK506治疗未能抑制这一现象。相比之下,0.5和1.0毫克/千克剂量的FK506治疗显著抑制了糖尿病大鼠肾脏中升高的ED-1(+)/iNOS(+)细胞。与正常大鼠相比,糖尿病阳性肾脏中的ED-1(+)/NF-κB-p-p65(+)细胞显著增加。0.5和1.0毫克/千克的FK506治疗显著减轻了糖尿病肾脏中升高的ED-1(+)/NF-κB-p-p65(+)细胞。此外,观察到ED-1(+)/iNOS(+)细胞与蛋白尿之间存在正相关(r = 0.87,p < 0.05)。同样,ED-1(+)/iNOS(+)细胞与nephrin和podocin蛋白均呈负相关(分别为r = -0.70,p < 0.05;r = -0.68,p < 0.05)。
我们的结果表明,FK506不仅上调nephrin和podocin的表达,还抑制巨噬细胞活化以保护足细胞免受损伤。